Cargando…
Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212217/ https://www.ncbi.nlm.nih.gov/pubmed/32399093 http://dx.doi.org/10.5114/aoms.2020.94503 |
| _version_ | 1783531578214842368 |
|---|---|
| author | Katsiki, Niki Banach, Maciej Mikhailidis, Dimitri P. |
| author_facet | Katsiki, Niki Banach, Maciej Mikhailidis, Dimitri P. |
| author_sort | Katsiki, Niki |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7212217 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Termedia Publishing House |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72122172020-05-12 Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic Katsiki, Niki Banach, Maciej Mikhailidis, Dimitri P. Arch Med Sci View Point Termedia Publishing House 2020-04-14 /pmc/articles/PMC7212217/ /pubmed/32399093 http://dx.doi.org/10.5114/aoms.2020.94503 Text en Copyright: © 2020 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
| spellingShingle | View Point Katsiki, Niki Banach, Maciej Mikhailidis, Dimitri P. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic |
| title | Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic |
| title_full | Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic |
| title_fullStr | Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic |
| title_full_unstemmed | Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic |
| title_short | Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic |
| title_sort | lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the covid-19 pandemic |
| topic | View Point |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212217/ https://www.ncbi.nlm.nih.gov/pubmed/32399093 http://dx.doi.org/10.5114/aoms.2020.94503 |
| work_keys_str_mv | AT katsikiniki lipidloweringtherapyandreninangiotensinaldosteronesysteminhibitorsintheeraofthecovid19pandemic AT banachmaciej lipidloweringtherapyandreninangiotensinaldosteronesysteminhibitorsintheeraofthecovid19pandemic AT mikhailidisdimitrip lipidloweringtherapyandreninangiotensinaldosteronesysteminhibitorsintheeraofthecovid19pandemic |